The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
There is an urgent need to explore therapeutic options for SARS-CoV-2 in order to face the
pandemic. The selected intervention was based on that zafirlukast will have dual effect;
first it will block the virus replication through inhibiting the COVID19 helicase that is
involved in virus replication and secondly by reducing the inflammation through antagonizing
the leukotriene receptor.
The purpose of this study is to evaluate the clinical efficacy and safety of Leukotriene
receptor antagonist in the treatment of moderate cases of COVID-19 patients.
Phase:
Phase 3
Details
Lead Sponsor:
King Abdullah International Medical Research Center